Trial Profile
A randomized, open-label study of the safety and tolerability of PEGASYS plus ribavirin in patients with chronic hepatitis C viral infection, genotype-1, and HIV-1 co-infection receiving, or discontinuing, highly active antiretroviral therapy (HAART).
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Antiretrovirals
- Indications Hepatitis C; HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 23 Jun 2006 New trial record.